Abbott puts flu vax unit up for sale; Vitae Pharma gets $14M milestone;

@FierceBiotech: Pharma pipelines mired by poor productivity, shrinking R&D budgets. Article | Follow @FierceBiotech

@JohnCFierce: IBM says that cloud computing can help reduce the 8-12% of trial costs related to data juggling. Article | @JohnCFierce

> Drug warehouses have become a big target for thieves, with the recent $75 million heist at Eli Lilly a high-profile example of the crime wave pharma faces. FiercePharmaManufacturing tracked the biggest capers in the country. Special Report

> Abbott Labs has put the flu vaccines unit it obtained in the Solvay buyout on the auction block, sources tell the Wall Street Journal. The business could fetch some €500 million, or $619 million. Story

> Fort Washington, PA-based Vitae Pharmaceuticals earned a $14 million milestone check on Boehringer Ingelheim's recent advancement of a small molecule inhibitor of 11beta-HSD-1 into Phase I clinical trials. Release

> Eli Lilly has signed on to collaborate with Marcadia Biotech on a new diabetes therapy. Richard DiMarchi, the former head of Lilly Research Labs, is CSO at Marcadia. No terms were announced. Story

> Depomed banked a $10 million milestone from Abbott Products, which is partnered on the pain drug DM-1796. Report

> Quintiles is investing up to $2 million in Prana Biotechnologies. "Quintiles has been intimately involved with Prana for a number of years and acted as the clinical research partner for Prana's last successful clinical trial," states a release. Release

> Hit with a sharp drop in sales, Synthetech has decided to bring in an adviser to review its options, including a possible sale of the company. Synthetech is a supplier of specialized chemicals to pharma companies. Report

And Finally...Researchers at the University of Illinois are studying baby pigs for fresh insights on the development of the infant brain and triggers for later behavioral problems. Report

Suggested Articles

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.

The series B positions ex-AveXis executives to build a biotech with a broad gene therapy pipeline and infrastructure to match.

A variant of the ACE2 receptor could work as a COVID-19 therapeutic by drawing the virus away from healthy cells, scientists reported.